RenovoRx, Inc. (RNXT) Cash Funds per Single Share

The targeted drug delivery technology is patent-protected, yet requires highly complex clinical trials. RenovoRx, Inc. (RNXT) has secured high recognition in oncology through the RenovoCath system, establishing a strong brand image. The optimization of catheter logistics and supplier diversification support high margins. Cash per share reflects the issuer's liquidity dynamics, where the value 0.22 shows the current magnitude of this financial indicator.
Analytical breakdowns for RenovoRx, Inc.

For RenovoRx, Inc. (RNXT), liquidity determines the pace of innovation adoption within the conservative oncology environment. This metric measures the volume of actual cash reserves available per share, excluding accounting noise. By analyzing the cash per share figure via GURU.Markets, an investor can see the company's real margin of safety. A decline in this indicator signals a risk of capital depletion amid fierce competition from traditional catheters. A stable level guarantees the development of the medtech project.